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effectiveness of fecal microbiota transplantation for the treatment of recurrent 
Clostridium difficile infection. The aim of this study is to evaluate the cost-effec-
tiveness of fecal microbiota transplantation compared with vancomycin for the 
treatment of Clostridium difficile infection in Australia. Methods: A Markov model 
was developed to compare the cost-effectiveness of fecal microbiota transplantation 
compared with standard antibiotic therapy. A literature review of clinical evidence 
informed the structure of the model and the choice of parameter values. Clinical 
effectiveness was measured in terms of quality adjusted life years. Uncertainty in 
the model was explored using probabilistic sensitivity analysis. Results: Using 
fecal microbiota transplantation rather than vancomycin saves AU$7,425 (95% CI: 
AU$2,252, AU$12,598) per Clostridium difficile infection patient. Fecal microbiota 
transplantation also leads to an incremental increase of 1.02 (95% CI 0.23, 1.81) 
life-years or 0.87 (95% CI 0.06, 1.68) quality adjusted life years per patient com-
pared with vancomycin. ConClusions: Based on current evidence, fecal micro-
biota transplantation is cost saving compared with standard antibiotic therapy for 
the treatment of recurrent Clostridium difficile infection. More research into the 
long-term safety and quality of life outcomes for patients receiving fecal microbiota 
transplantation is warranted.
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objeCtives: Hepatic encephalopathy (HE) is associated with high morbidity and 
mortality. Rifaximin-α is effective in reducing the recurrence of episodes of overt 
HE, and reduces hospital utilisation. The objective was to characterise the cost effec-
tiveness of rifaximin-α plus a standard of care (SOC) versus SOC alone (lactulose) 
in patients with liver cirrhosis in Belgium. Methods: This economic evaluation 
used a Markov state transition model. The outcome metric was the incremental 
cost effectiveness ratio (ICER), derived from estimates of the cost/quality adjusted 
life years (QALYs). The payer perspective was that of the Belgian healthcare system. 
Outcome data were from two trials of rifaximin-α . Belgian costs data (2010) were 
derived from published sources. Health-related utility was estimated indirectly from 
disease-specific quality of life RCT data. The time horizon was five years. Costs and 
benefits were discounted at 3% and 1.5%, respectively. Real world data were also 
applied into the model for length of hospital stay (LOHS) and number of admis-
sions. Results: Average costs of the included elements of care were € 31,262 in 
the rifaximin-α + SOC arm and € 44,190 in the SOC arm, a difference of € 12,927. The 
corresponding values for benefit were 2.5 and 1.9 QALYs per person, respectively, 
a difference of 0.6 QALYs over the five year period. This translated into a dominant 
base-case ICER at five years, ten years and for a lifetime simulation, meaning that 
compared to SOC, rifaximin-α + SOC improves quality of life and offers savings to 
the Belgian healthcare system. Key parameters impacting the ICER included LOHS 
and number of hospital admissions. ConClusions: By reducing overt HE episodes, 
the likelihood of hospital admission and LOHS, rifaximin-α 550 mg + SOC in patients 
with recurrent HE in the context of liver cirrhosis, represented good value and was 
cost-saving compared with SOC.
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objeCtives: The aim of this study was assessing cost-utility of infliximab compared 
with current treatments in patients with moderate to severe ulcerative colitis (UC) in 
Iran. Methods: We constructed a decision tree model with 5 year time horizon to 
follow up 1000 hypothetical patients for estimating treatment costs and outcomes. 
Patients were individuals with moderate to severe UC that is resistant to current 
treatments. Remission rate, clinical response and surgery were selected as clini-
cal outcomes. Then for estimating QALY, utility value related to each state drive 
form published literature. We also estimated associated probabilities using patients 
‘medical records and specialists’ opinion. Costs of treatment including physician 
visits, laboratory tests, hospitalizations, surgery and drugs were estimated based on 
the public and private sector tariffs and drug price list that set by pricing committee 
of food and drug administration. Infliximab costs at dosage of 5 mg /kg were cal-
culated for UC patients with average weight of 75 kilogram. Results: Incremental 
cost-utility ratio of infliximab treatment in UC patients estimated with public and 
private sector tariffs were 18 260 and 188 366 dollars per QALY gained compared with 
current treatments, respectively. ConClusions: According to recommendation of 
world health organization for choosing cost effective intervention, interventions 
with relative cost effectiveness value less than 3 time of gross domestic production 
per capita are cost –effective. So for UC patients, our finding indicates that ICUR 
values with public and private sector tariffs are more than 3 time of local GDP 
per capita, 3.8 and 39.5 respectively and infliximab treatment is not cost effective.
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objeCtives: Calcineurin inhibitors represent the cornerstone of immunosuppres-
sive therapy after liver transplantation. A recent Bayesian network meta-analysis 
model. These included the rates of response and remission during the induction 
period. Adverse events were also important; however, only those for standard care 
were key drivers in the submission, while adverse event rates for both treatments 
were important in the reconstructed model. ConClusions: Rates of response, 
remission and adverse events are important drivers of cost effectiveness in Crohn’s 
disease.
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objeCtives: Compared to infection with hepatitis C virus (HCV) alone, patients 
co-infected with HIV have faster disease progression, decreased quality of life 
and increased rates of mortality. The objective of this study was to compare 
the cost-effectiveness of novel, all oral direct-acting antiviral regimens for the 
treatment of HCV/HIV co-infected patients. Methods: A published, validated 
Markov model was used to model a cohort of HCV/HIV co-infected patients 
(mean age 50 years, 50% female, evenly distributed across F0–F4) treated with 12 
weeks daclatasvir+sofosbuvir (DCV+SOF) versus 24 weeks sofosbuvir+ribavirin 
(SOF+RBV). Clinical inputs were obtained from a matching-adjusted indirect 
comparison (MAIC) of ALLY-2 (DCV+SOF: adjusted SVR= 100.0%) and PHOTON-1/-2 
(SOF+RBV: adjusted SVR= 84.6%). HIV co-infection- and HCV genotype-specific 
transition rates were applied and analyses combined and weighted per MAIC 
values (genotypes 1 & 4= 56.5%; 2= 16.5%; and 3= 27.0%). UK acquisition costs 
(DCV= £2,043.15, SOF= £2,915.24 and RBV= £66.95 per week), disease state costs 
(2014) and health utility values were used. Costs and benefits were discounted 
at 3.5%. Results: Reduced total costs and increased QALYs were estimated for 
DCV+SOF versus SOF+RBV, resulting in DCV+SOF dominating in terms of cost-
effectiveness. Predicted discounted total costs were £239,213 versus £250,014, 
respectively. Whilst the cost of HIV management increased by £5,237 per person 
due to the increase in life expectancy (19.20 discounted years versus 18.64) with 
DCV+SOF, there was a reduction in HCV management costs of £5,695 as a conse-
quence of avoiding end-stage liver disease (ESLD) complications. Predicted dis-
counted QALYs were 11.56 versus 10.91, respectively. ConClusions: The results 
of this analysis demonstrate that significant value might be realised by the use of 
DCV+SOF over SOF+RBV in patients co-infected with HIV and HCV. Cost-savings 
and QALY gains for the DCV+SOF regimen are driven by the shorter treatment 
duration and higher SVR, resulting in lower overall acquisition costs and fewer 
ESLD complications.
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objeCtives: Gut-directed hypnotherapy (HT) is effective for irritable bowel syn-
drome (IBS) and functional abdominal pain (syndrome) (FAP(S)) in children. We 
assessed the cost-utility and cost-effectiveness of HT by self-exercises at home 
using a compact disc (CD) against individual HT performed by a qualified hypno-
therapist (iHT). Methods: Alongside a multicentre non-inferiority randomized 
controlled trial among children with IBS and FAP(S) data on treatment response, 
quality of life (Health Utility Index 3) and societal and health care costs were 
gathered at baseline (T0), end of treatment (T1) and 6 (T2) and 12 (T3) months 
thereafter. Incremental cost-effectiveness ratios with the extra costs per responder 
and per QALY were estimated and the cost-effectiveness acceptability of CD was 
assessed for various levels of willingness to pay (WTP) following non-parametric 
bootstrapping. Results: After one year, CD treatment resulted in cost savings 
of € 397 (95% bca CI: -€ 794 to -€ 26; P= 0.038) compared to iHT. Treatment response 
in the CD group (62.1%) was non-inferior to the iHT group (71.1%). Offering CD 
treatment instead of iHT treatment saves € 4,411 per treatment non-responder. 
After correction for differences in health utility at baseline, the mean difference 
in QALYs (0.014 (95% bca CI: -0.032 to 0.060) slightly favoured CD treatment. The 
probability that CD treatment is both, cost saving and gaining QALYs, equals 69.7%; 
the probability that CD is cost-effective equals 0.825 at a reasonable WTP in chil-
dren of € 50,000. ConClusions: Home-based treatment with HT exercises on CD 
for children with IBS or FAP(S) is non-inferior and seems cost-effective compared 
to individual HT with a qualified therapist and could therefore be offered as first 
line treatment.
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objeCtives: Clostridium difficile is the most common cause of hospital-acquired 
diarrhea in Australia. In 2013, a randomized controlled trial demonstrated the 
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objeCtives: Patients with ulcerative colitis reported that the complexity of the 
treatment regimen, the amount and frequency of administration of the therapy 
are key elements in influencing non-adherence to therapy. Methods: The objec-
tive of this work was to evaluate the perception of patients with ulcerative coli-
tis compared to adherence to treatment, through a questionnaire distributed by 
clinicians of some Italian hospitals to patients with ulcerative colitis. Results: 
The survey involved 1,064 patients with an average age of 48 years, with a range 
between 5 and 90 years; 46% of the sample is female, 54% are males. More than 50% 
of patients surveyed has a disease duration of less than 10 years and about 35% last 
less than 5 years (median 8 years). There is a prevalence of cases of ulcerative left 
(51%). About 34% reported pancolitis, 14% proctitis and 0.5% chron. The 73% denied 
having adherence issues; the perception of adequate intake of therapy is almost 
complete: only 19% admit to not be adherent. The main reason for non-adherence 
to treatment, regardless of the formulation prescribed, remains forgetfulness (48%), 
followed by the fact of feeling good (20%). In this respect there is a significant differ-
ence depending on whether the disease is in the active phase (47%) or in remission 
(67%). ConClusions: There is a strong adherence by patients, discordant from the 
literature. As regards the reasons for the non-adherence in the low percentage in our 
study, this result appears instead in line with what reported in literature. The direct 
consequence of a failure or suboptimal adherence to treatment involves more than 
the increase in the risk of recurrence of the disease, since patients often interrupt 
chronic medication because they feel good, even a simultaneous increase in costs 
borne by patients and health care system.
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objeCtives: The EQ-5D is a standardized, non-disease-specific instrument for 
describing and valuing patients’ health-related quality of life (HRQoL). The aim 
of this study was to measure HRQoL with the use of the EQ-5D and to compare 
it with the self-evaluation of health state in patients with inflammatory bowel 
disease (IBD). Methods: An online survey was performed. After having given 
informed consent and in order to gain experience with time trade-off (TTO) 
method, patients randomly chose two EQ-5D health states and assigned them 
appropriate utilities. Then, they were asked to assess their own health state by 
the means of EQ-5D, Visual analogue scale (VAS) and TTO. Results: 169 patients 
(76M, 93F) completed EQ-5D, VAS and TTO. Mean age of respondents was 29.9±8.98 
years (range: 18 to 61).73 patients suffered from ulcerative colitis (UC) and 84 from 
Cohn’s disease (CD). In 40 patients the diagnosis was made within one year, 91 
patients were 1-9 years and 38 at least 10 years since diagnosis. 43 patients had 
an operation because of IBD. Respectively, 30, 11, 67, 123 and 117 patients had at 
least moderate deterioration in domains: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Mean EQ-5D value (using Polish TTO norms) 
was 0.829±0.162 and mean VAS score was 64.23±21.17. There was a significant 
correlation between EQ-5D and self-evaluation of health state (mean value 0.83, 
r= 0.279, p< 0.001). There was no statistically significant difference in any of the 
subgroup analyses in any of the subgroup analyses (CD vs. UC: 0.821 vs. 0.839, ≤ 1 
year vs. 1-9 years vs. ≥ 10 years from diagnosis: 0.827 vs. 0.815 vs. 0.866, operation 
vs. only conservative treatment: 0.823 vs. 0.831, p> 0.05). ConClusions: EQ-5D 
appeared valid and informative in Polish IBD patients. However, it seems not to be 
sensitive enough to distinguish between different subgroups in this heterogeneous 
population.
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objeCtives: In order to make decisions experts and patients have to face trade-
offs between benefit and harms. Harms can be expressed as the risk of occurrences 
and also the severity. Ideally a combination of both should be taken into account 
when making decisions. In the context of approval, allocation decisions and benefit 
assessment, the question arises as risk and severity of side-effects are included in 
the decision making process. Methods: The discrete choice experiment used com-
pound side-effect attributes of a hepatitis C treatment by combining severity and 
risk. Thus, patients’ preferences regarding the probability of occurrence and severity 
of side-effects could be measured. The decision model included sustained-virologi-
cal-response, duration of therapy and number of interferon injections and five com-
pound side-effect attributes: rash, anemia, nausea/diarrhea, tiredness/fatigue and 
headache. The compound attribute were composed out of risk and severity, resulting 
in 6 levels per attribute. The experimental design (3*3+5*6) (Ngene) consisted of 
72choices, which were divided into 6 blocks. Results: N= 561 hepatitis C-patients 
(58.1%male) participated in computer-assisted personal interviews. Within the 
random parameter logit model (95%CI) the preference analysis could show that 
participants valued severity and risk of side-effects differently. The analysis of the 
six levels e.g. for the side-effect “anemia” was weighted the following: coef.“mild 
(NMA) has evaluated the relative efficacy of ciclosporin, prolonged-release (PR) 
and immediate-release (IR) tacrolimus in adult liver transplant recipients based on 
randomized controlled trials and large observational studies published since 2000. 
Based on the NMA findings, the present study evaluated the cost-utility of using 
PR tacrolimus relative to ciclosporin or IR tacrolimus in liver transplant recipi-
ents in the UK setting. Methods: A Markov model was developed in Microsoft 
Excel to evaluate the cost-effectiveness of immunosuppressive regimens in liver 
transplant recipients. The model captured costs associated with immunosup-
pression, retransplantation and acute rejection (AR). Mortality, graft loss and 
AR odds ratios were derived from the NMA. Costs were taken from the British 
National Formulary and the NHS National Tariff and expressed in 2014 pounds 
sterling. Future costs and effects were discounted at 3.5% annually. Results: Over 
a 25-year time horizon, PR tacrolimus resulted in increased life expectancy and 
quality-adjusted life expectancy (QALE) relative to IR tacrolimus and ciclosporin. 
Relative to ciclosporin, QALE increased by 1.17 quality-adjusted life years (QALYs) 
with PR tacrolimus while costs increased by GBP 18,107, yielding an incremen-
tal cost-effectiveness ratio (ICER) of GBP 15,443 per QALY gained. Relative to IR 
tacrolimus, QALE increased by 0.78 QALYs and costs by GBP 1,646, resulting in an 
ICER of GBP 1,646 per QALY gained. Sensitivity analysis showed the analysis to be 
most sensitive to the dosing assumptions. ConClusions: Based on a UK-specific 
analysis of the projected cost and effectiveness of PR tacrolimus relative to IR 
tacrolimus and ciclosporin, PR tacrolimus improved life expectancy and quality-
adjusted life expectancy relative to both IR tacrolimus and ciclosporin. While 
costs of PR tacrolimus were higher, the incremental cost-effectiveness ratios fell 
below GBP 20,000.
PGI38
EvaluatIon of thE Cost EffECtIvEnEss and soCIEtal ImPaCt of 
RIfaxImIn-Á 550mG In thE REduCtIon of RECuRREnCE of ovERt hEPatIC 
EnCEPhaloPathy In thE nEthERlands
Whitehouse JT1, Berni E2, Conway P3, Radwan A4, Henrar R5, Currie CJ6
1Norgine, Uxbridge, UK, 2Pharmatelligence, Cardiff, UK, 3Norgine Ltd, Harefield, UK, 4Norgine Ltd, 
Uxbridge, UK, 5Norgine B.V, Amsterdam, The Netherlands, 6Cardiff University, Cardiff, UK
objeCtives: Hepatic encephalopathy (HE) is associated with high morbidity and 
mortality. Rifaximin-α 550mg is effective in reducing the recurrence of overt HE 
episodes, and hospital utilisation. We characterised the cost effectiveness includ-
ing societal impact of rifaximin-α 550mg plus a standard of care (SOC) versus SOC 
alone (lactulose) in patients with liver cirrhosis in The Netherlands. Methods: A 
Markov state transition model was used. Outcome metrics were incremental cost 
effectiveness ratios (ICERs), derived from cost/quality adjusted life years (QALYs) 
estimates and estimates of impact of work productivity loss upon patient/carer 
using a friction cost method reflecting patient and societal considerations in the 
model. Outcomes data were from two trials of rifaximin-α 550mg. Dutch costs data 
(2010) were derived from published sources and societal cost estimates were from 
the Dutch costing manual (2010) inflated to 2015 prices. Health-related utility was 
estimated indirectly from disease-specific quality of life RCT data. The time horizon 
was five years. Costs and benefits were discounted at 4% and 1.5%, respectively. Real 
world data were applied into the model for length of hospital stay and number of 
admissions. Results: 5 year average costs of included care/societal elements was 
€ 88,386 in the rifaximin-α 550mg + SOC arm and € 82,968 in the SOC arm, a € 5,418 
difference. Corresponding values for benefits were 2.45 and 1.89 QALYs/person, 
respectively, a difference of 0.56 QALYs over five years. This translated into a cost 
effective base-case ICER of € 9,576 at a five year time horizon. ConClusions: Use 
of rifaximin-α 550 mg + SOC in patients with recurrent HE in the context of liver 
cirrhosis represented good value and was cost-effective compared with SOC alone, 
by reducing overt HE episodes, the likelihood of hospital admission and hospital 
length of stay.
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objeCtives: Hepatitis B infection is the major cause of chronic liver disease in 
Iran.This study has been designed to evaluate the cost-effectiveness of different 
options of medication therapy for CHB in Iran. Methods: An economic evaluation 
of cost-utility was conducted to assess five oral medication strategies including: 
Adefovir, Lamivudine, Adefovir + Lamivudine, Entecavir, and Tenofovir. A Markov 
micro-simulation model was used to estimate the clinical and economic out-
comes in a life time horizon and based on a societal perspective. Medical and 
non-medical direct costs and indirect costs were included in the study and Life-
Years Gained (LYG) and Quality-Adjusted Life-Years (QALY) were determined as 
the measures of effectiveness. The results were presented in terms of Incremental 
Cost Effectiveness Ratio (ICER) per QALY or LYG. The model was consisted of nine 
states of the disease; the transition probabilities for the movement between the 
states were obtained using clinical evidences and expert opinions collected from 
all over the world. Probabilistic sensitivity analyses (PSA) was used to measure 
the effects of uncertainty in model parameters. Results: Results found that 
the Tenofovir treatment strategy was more effective and less costly than other 
options. In addition, Tenofovir had the highest QALY and LYG for the HBeAg -ve 
and HBeAg +ve with 13.52 and 15.21; 2133 and 21.53 (discounted) in all compari-
sons, respectively. Also, PSA proved the robustness of the model results. So that, 
The cost-effectiveness acceptability curves showed that TDF was the most cost-
effective treatment in 86.1% and 87.7% of the simulations for the HBeAg -ve and 
HBeAg +ve with WTP thresholds less than PPP $ 45270 (maximum WTP per QALY), 
respectively. ConClusions: The results showed that using Tenofovir in patients 
with CHB was a highly cost-effective strategy.
